SCNX

Peers: ETON EBS INDV AYTU AQST CPIX SUPN ZVRA CING TNXP

Index	-
Market Cap	5.31M
Enterprise Value	7.81M
Income	-20.55M
Sales	0.65M
Book/sh	39.03
Cash/sh	4.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	9
IPO	Jan 26, 2009

P/E	-
Forward P/E	-
PEG	-
P/S	8.16
P/B	0.08
P/C	0.65
P/FCF	-
EV/EBITDA	-
EV/Sales	12.01
Quick Ratio	2.97
Current Ratio	3.04
Debt/Eq	0.17
LT Debt/Eq	0.15
Option/Short	No / Yes

EPS (ttm)	-45.23
EPS next Y	-0.27
EPS next Q	-1.57
EPS this Y	93.42%
EPS next Y	93.92%
EPS next 5Y	-
EPS past 3/5Y	23.94% 11.34%
Sales past 3/5Y	-65.21% -52.10%
EPS Y/Y TTM	92.38%
Sales Y/Y TTM	-73.18%
EPS Q/Q	78.08%
Sales Q/Q	3249.96%
Earnings	Aug 14 BMO
EPS/Sales Surpr.	22.22% -

Insider Own	22.08%
Insider Trans	0.00%
Inst Own	5.30%
Inst Trans	-
ROA	-20.29%
ROE	-24.07%
ROIC	-27.90%
Gross Margin	82.75%
Oper. Margin	-2648.49%
Profit Margin	-3145.84%
SMA20	-3.26%
SMA50	-47.62%
SMA200	-64.65%
Trades

Shs Outstand	1.64M
Shs Float	1.28M
Short Float	8.27%
Short Ratio	0.55
Short Interest	0.11M
52W High	27.75 -88.36%
52W Low	2.64 22.35%
Volatility	9.69% 14.21%
ATR (14)	0.43
RSI (14)	32.20
Beta	3.51
Rel Volume	0.04
Avg Volume	190.79K
Volume	4,651

Perf Week	10.24%
Perf Month	-18.64%
Perf Quarter	-65.64%
Perf Half Y	-66.96%
Perf YTD	-74.67%
Perf Year	-83.35%
Perf 3Y	-96.48%
Perf 5Y	-99.67%
Perf 10Y	-99.65%
Recom	1.00
Target Price	6.00
Prev Close	3.22
Price	3.23
Change %	0.31%

Oct-22-26 08:05AM	SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 (GlobeNewswire)
Oct-13-26 08:05AM	SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth (GlobeNewswire) -17.14%
Oct-02-26 08:05AM	SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals (GlobeNewswire) -10.33%
Sep-30-26 04:05PM	Scienture Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire) -31.83%
Sep-22-26 08:15AM	SCIENTURE Expands Commercial Reach of REZENOPY to Addiction Treatment Centers through an Agreement with a Distribution Partner (GlobeNewswire) -6.43%
08:55AM	Loading…
Sep-09-26 08:55AM	SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 (GlobeNewswire)
Aug-14-26 08:08AM	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance (GlobeNewswire)
Aug-13-26 06:38PM	Scienture Holdings: Q2 Earnings Snapshot (Associated Press)
Aug-12-26 10:13AM	SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product (InvestorsHub) +10.00%
08:05AM	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY, the Highest Dose FDA-Approved Naloxone Nasal Spray (GlobeNewswire)
Jul-09-26 08:05AM	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (naloxone hydrochloride) to Wholesalers (GlobeNewswire)
Jun-18-26 08:05AM	SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide (GlobeNewswire)
Jun-09-26 08:05AM	SCIENTURE Secures Formulary Coverage for REZENOPY with a Large National Health Plan and Expands Commercial Team (GlobeNewswire)
Jun-04-26 08:00AM	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC (ACCESSWIRE)
Jun-02-26 08:05AM	SCIENTURE Receives U.S. Patent Covering REZENOPY (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 (GlobeNewswire)
08:38AM	Loading…
May-18-26 08:38AM	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion (GlobeNewswire)
May-15-26 04:58PM	Scienture Holdings: Q1 Earnings Snapshot (Associated Press)
May-07-26 08:05AM	Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline (GlobeNewswire) +8.64%
May-06-26 08:05AM	SCIENTURE Announces Third Patent Grant for ARBLI (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 (GlobeNewswire)
Apr-15-26 08:05AM	Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire) +16.68%
Apr-06-26 08:05AM	Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead (GlobeNewswire) +10.26%
Mar-30-26 08:32AM	Scienture Holdings: Q4 Earnings Snapshot (Associated Press) -42.23%
08:07AM	SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-11-26 08:05AM	SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions (GlobeNewswire) +19.46%
Feb-03-26 08:05AM	SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium (GlobeNewswire)
Jan-14-26 08:05AM	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment (GlobeNewswire)
07:51AM	EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment (Benzinga)
Dec-22-25 08:05AM	SCIENTURE Provides Update on the Commercial Launch of REZENOPY, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA (GlobeNewswire) -8.61%
Dec-11-25 08:20AM	Scienture, BlinkRx announce strategic collaboration to expand access to Arbli (TipRanks)
Dec-10-25 08:05AM	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium (GlobeNewswire)
09:00AM	Loading…
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-02-25 08:05AM	SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9-10, 2025 (GlobeNewswire)
Nov-13-25 08:05AM	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.47%
07:50AM	EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction (Benzinga)
Nov-12-25 05:49PM	Scienture Holdings: Q3 Earnings Snapshot (Associated Press Finance)
Nov-04-25 08:05AM	SCIENTURE Announces Addition of Arbli (Losartan Potassium) to Formularies of Major National Health Plans (GlobeNewswire) +15.35%
07:51AM	EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives (Benzinga)
Oct-23-25 08:05AM	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli (Losartan Potassium) (GlobeNewswire) +354.94%
07:51AM	EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients (Benzinga)
Oct-16-25 09:00AM	SCIENTURE'S Arbli Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers (GlobeNewswire) -17.63%
Oct-08-25 09:00AM	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet (GlobeNewswire)
Oct-01-25 09:00AM	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli (losartan potassium) to more than 2500 Healthcare Institutions (GlobeNewswire)
08:46AM	EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions (Benzinga)
Sep-16-25 08:05AM	SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli(losartan potassium) in the $256M U.S. Losartan Market (GlobeNewswire)
07:45AM	EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market (Benzinga)
Aug-14-25 09:00AM	Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock (GlobeNewswire) -45.50%
Aug-13-25 08:05AM	SCIENTURE announces the shipment of launch quantities of Arbli (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. (GlobeNewswire) +6.22%
Aug-12-25 02:07PM	Scienture Holdings: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 05:12PM	Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding (GlobeNewswire) -5.58%
Jul-16-25 08:15AM	Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +19.88%
Jun-17-25 08:05AM	Scienture Holdings Announces Cancelation of ELOC (GlobeNewswire) -8.57%
May-22-25 08:05AM	SCIENTURE Announces Executive Leadership Transition (GlobeNewswire)
May-19-25 08:05AM	SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. (GlobeNewswire) +6.51%
Apr-22-25 08:05AM	SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. (GlobeNewswire)
Apr-08-25 08:05AM	SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. (GlobeNewswire) -8.17%
Apr-03-25 08:26AM	Scienture Holdings, Inc. Issues Annual Letter to Shareholders (GlobeNewswire) -16.13%
Mar-25-25 08:05AM	SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization (GlobeNewswire) -7.33%
Mar-19-25 08:05AM	Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days (GlobeNewswire) +19.50%
Mar-18-25 08:05AM	SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. (GlobeNewswire) -35.89%
Mar-06-25 07:40AM	SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. (GlobeNewswire) +9.55%
Jan-21-25 08:05AM	Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics (GlobeNewswire)
Dec-17-24 08:05AM	Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025 (GlobeNewswire)
Dec-10-24 08:05AM	Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041 (GlobeNewswire) +6.48%
Nov-26-24 04:05PM	Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement (GlobeNewswire) -5.37% +8.02%
Sep-24-24 08:01AM	TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to SCNX (GlobeNewswire)
Sep-20-24 11:59AM	TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. (GlobeNewswire)
Aug-05-24 08:01AM	TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team (GlobeNewswire) -15.66%
Jul-26-24 08:01AM	TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million (GlobeNewswire) +9.97%
Jul-09-24 08:05AM	TRxADE Health, Inc. Announces Special Cash Dividend (GlobeNewswire) +5.31%
Jun-27-24 08:00AM	TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale (GlobeNewswire) +11.05%
Jun-26-24 10:52PM	MEDS Stock Earnings: Trxade Health Reported Results for Q1 2024 (InvestorPlace) +35.12%
01:38PM	TRxADE: Q1 Earnings Snapshot (Associated Press Finance)
May-29-24 04:05PM	TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) +14.59%
Apr-28-24 12:01PM	12 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-23-24 04:05PM	TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K (GlobeNewswire)
Mar-06-24 08:05AM	TRxADE Health, Inc. Announces Special Cash Dividend (GlobeNewswire) +107.21%
Feb-20-24 08:14AM	Why Is Trxade Health (MEDS) Stock Up 230% Today? (InvestorPlace) +98.04%
Jan-17-24 09:07AM	Trxade health, Inc files its 3Q 10Q (GlobeNewswire)
Jan-16-24 04:12PM	TRxADE: Q3 Earnings Snapshot (Associated Press Finance)
Nov-29-23 06:13PM	TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q. (GlobeNewswire)
Oct-17-23 08:05AM	TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023. (GlobeNewswire)
Oct-12-23 08:05AM	Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales (GlobeNewswire)
Oct-04-23 08:05AM	Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry. (GlobeNewswire)
Sep-07-23 09:00AM	TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc. (ACCESSWIRE)
08:05AM	Superlatus Announces Planned Expansion into Pet Food Market (GlobeNewswire)
Aug-24-23 08:05AM	Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand (GlobeNewswire)
Aug-22-23 08:05AM	Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc. (GlobeNewswire) -7.74%
Aug-14-23 10:25AM	TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing (GlobeNewswire) -9.80%
Aug-03-23 09:05AM	Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team (GlobeNewswire) -19.55%
Jul-31-23 04:15PM	TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m. Eastern Time (ACCESSWIRE) -9.57%
08:35AM	TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc. (GlobeNewswire)
Jul-14-23 04:30PM	TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc. (GlobeNewswire) -7.55%
Jun-30-23 08:05AM	Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution (GlobeNewswire)
Jun-27-23 08:00AM	Superlatus, Inc. Announces New Appointments to the Management Team (GlobeNewswire) -9.29%
Jun-23-23 04:40PM	TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice) (GlobeNewswire) +15.62% +93.84%
08:05AM	Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform (GlobeNewswire)
Jun-21-23 12:36PM	TRxADE Health, Inc.s Board of Directors Approves Reverse Stock Split (GlobeNewswire) +16.64%
May-17-23 01:56PM	TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-16-23 07:52AM	Q1 2023 TRxADE Health Inc Earnings Call (Thomson Reuters StreetEvents) -16.33%
May-15-23 06:15PM	TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)

Show Previous News

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Commack, NY.

FounderDr. Shankar Hariharan Ph.D.

Ph.D.Mr. Rahul Surana M.B.A.

Senior VP & Chief Commercial Officer of Scienture LLCMs. Michele Rath

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Scienture Holdings Inc

Upgrade your Finviz experience